Clinical Research Directory
Browse clinical research sites, groups, and studies.
Adverse Event Data Collection From the EUHASS Registry on Turoctocog Alfa Pegol
Sponsor: Novo Nordisk A/S
Summary
This non-interventional study concerns a safety data collection based on adverse event data from a third-party registry (European Haemophilia Safety Surveillance System, EUHASS) that includes information about adverse events from patients with haemophilia A treated with turoctocog alfa pegol. There is no extra burden to the patients by participating in this registry-based data collection.
Key Details
Gender
All
Age Range
Any - Any
Study Type
OBSERVATIONAL
Enrollment
50
Start Date
2020-12-09
Completion Date
2026-02-01
Last Updated
2025-09-25
Healthy Volunteers
No
Conditions
Interventions
Turoctocog alfa pegol
Patients will be treated with commercially available turoctocog alfa pegol according to routine clinical practice at the discretion of the treating physician. A decision to initiate treatment with commercially available turoctocog alfa pegol has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in the registry in scope.
Locations (1)
Novo Nordisk Investigational Site
Søborg, Denmark